MK0524 Asthma POC Study (0524-008)(COMPLETED)

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to demonstrate the benefit of MK0524 compared to placebo in patients with chronic asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Has symptoms of chronic asthma (shortness of breath, wheezing, chest tightness, etc.) for at least 1 year

• Nonsmoker for at least 1 year with a smoking history of no more than 7 pack-years (i.e., 1 pack per day for 7 years)

Exclusion Criteria:

• Any clinically significant disease of heart, intestinal, kidney, liver, lung or uncontrolled blood pressure

• Any surgery within 4 weeks prior to Visit 1

• Patient is intending to move or vacation for more than 5 days during the study

• Patient is pregnant or breast-feeding